Biotech Values

[biocqr]

IDRA update...

Baker Bros bought 4.5M shares in public offering on May 1..
http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1814044&highlight=

http://whalewisdom.com/stock/idra

May 8... reported P2 results on TLR antagonist IMO-3100 for moderate to severe psoriasis...

Clinical Activity:
On day 57, 48% of patients treated with either dose of IMO-3100 (12 of 25) demonstrated statistically significant improvements of 35% to 90% from baseline PASI scores compared with 0 of 12 in the placebo cohort (p<0.005)

http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1816887&highlight=

Poster...
https://docs.google.com/viewer?url=http%3A%2F%2Fwww.iderapharma.com%2Fdevelopment%2FIID_Poster_2013.pdf

June 5 ...Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis
http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1827173&highlight=

On July 10 hired a new Chairman of BOD ...

James Geraghty is a life sciences industry leader. Currently an Entrepreneur-in-Residence at Third Rock Ventures, Jim served as Senior Vice President, North America Strategy and Business Development at Sanofi, where he was a member of the Office of the CEO. Prior to Sanofi's acquisition Jim spent 20 years at Genzyme Corporation, most recently as Senior Vice President, and helped Genzyme introduce rare disease therapies around the world. His roles included President of Genzyme Europe, where he oversaw several new product launches, and General Manager of Genzyme's cardiovascular business, where he guided the development of a recently approved antisense product. He also led strategic transactions that brought important new products into Genzyme, as well as divestitures valued at over $1 billion. He was previously Chairman, President and CEO of Genzyme Transgenics Corporation (later GTC Biotherapeutics), which he founded and took public. Jim served as co-chair of the executive committee for BIO 2007, was for a number of years a member of the board of Bluebird Bio, and continues to serve on the board of Bio Ventures for Global Health (BVGH). A graduate of the Yale Law School, he has published articles in the Yale Law Journal, Health Affairs and elsewhere. He holds an MS from the University of Pennsylvania and a BA from Georgetown University.

Geraghty bought 300K shares @ 1.75 on Aug 20...

http://www.sec.gov/Archives/edgar/data/861838/000120919113041552/xslF345X03/doc4.xml